|
Market Cap (18-May) $8,414,961,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (5-May) 16,072,273 (4.76%) (53rd) |
|
52w High $31.97 |
52w Low $14.42 |
P/E 57.80 |
EPS 0.15 |
TLX released this announcement to the ASX on 21 December 2021, 8:25. The announcement is marked as price sensitive, and is 3 page(s) in length and 217.57kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 0.532% short sold according to ASIC data. It was ranked the 269th most shorted stock on the ASX. It is now ranked as the 53rd most shorted stock on the ASX with 4.757% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| Targeted Alpha Therapy for Bladder Cancer 1st patient dosed | 21 December 2021, 8:25 |
| FDA Approves Telix Prostate Cancer Imaging Product Illuccix | 20 December 2021, 8:27 |
| Illuccix EU Regulatory Submission Progress Update | 10 December 2021, 8:19 |
| NUCLIBER - Distribution Agreement for Illuccix in Spain | 8 December 2021, 8:20 |
You must be logged in to post a reply.
Telix Pharmaceuticals 